Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123


Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.

Demicco EG, Boland GM, Brewer Savannah KJ, Lusby K, Young ED, Ingram D, Watson KL, Bailey M, Guo X, Hornick JL, van de Rijn M, Wang WL, Torres KE, Lev D, Lazar AJ.

Histopathology. 2015 Apr;66(5):627-38. doi: 10.1111/his.12466. Epub 2015 Jan 12.


Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors.

Robin YM, Penel N, Pérot G, Neuville A, Vélasco V, Ranchère-Vince D, Terrier P, Coindre JM.

Mod Pathol. 2013 Apr;26(4):502-10. doi: 10.1038/modpathol.2012.192. Epub 2012 Nov 23.


Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker.

Hisaoka M, Wei-Qi S, Jian W, Morio T, Hashimoto H.

Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):302-8.


h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.

Nucci MR, O'Connell JT, Huettner PC, Cviko A, Sun D, Quade BJ.

Am J Surg Pathol. 2001 Apr;25(4):455-63.


Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects.

Waldmann J, Stachs A, Terpe H, Stropahl G, Makovitzky J.

Anticancer Res. 2005 May-Jun;25(3A):1559-65.


An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.

Allen MM, Douds JJ, Liang SX, Desouki MM, Parkash V, Fadare O.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2795-801. eCollection 2015.


Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus.

de Leval L, Waltregny D, Boniver J, Young RH, Castronovo V, Oliva E.

Am J Surg Pathol. 2006 Mar;30(3):319-27.


Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Beck AH, Lee CH, Witten DM, Gleason BC, Edris B, Espinosa I, Zhu S, Li R, Montgomery KD, Marinelli RJ, Tibshirani R, Hastie T, Jablons DM, Rubin BP, Fletcher CD, West RB, van de Rijn M.

Oncogene. 2010 Feb 11;29(6):845-54. doi: 10.1038/onc.2009.381. Epub 2009 Nov 9.


Vascular leiomyosarcoma: Clinicopathology and immunohistochemistry with special reference to a unique smooth muscle phenotype.

Matsuyama A, Hisaoka M, Hashimoto H.

Pathol Int. 2010 Mar;60(3):212-6. doi: 10.1111/j.1440-1827.2009.02508.x.


From PTEN loss of expression to RICTOR role in smooth muscle differentiation: complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas.

Gibault L, Ferreira C, Pérot G, Audebourg A, Chibon F, Bonnin S, Lagarde P, Vacher-Lavenu MC, Terrier P, Coindre JM, Aurias A.

Mod Pathol. 2012 Feb;25(2):197-211. doi: 10.1038/modpathol.2011.163. Epub 2011 Nov 11.


Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas.

Lee CH, Roh JW, Choi JS, Kang S, Park IA, Chung HH, Jeon YT, Kim JW, Park NH, Kang SB, Song YS.

Int J Gynecol Cancer. 2011 May;21(4):668-72. doi: 10.1097/IGC.0b013e3182150d56.


Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups.

Carvalho JC, Thomas DG, Lucas DR.

Cancer. 2009 Sep 15;115(18):4186-95. doi: 10.1002/cncr.24486.


Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry.

Mills AM, Beck AH, Montgomery KD, Zhu SX, Espinosa I, Lee CH, Subramanian S, Fletcher CD, van de Rijn M, West RB.

Am J Surg Pathol. 2011 Apr;35(4):583-9. doi: 10.1097/PAS.0b013e318211abd6.


Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases.

Nicolas MM, Tamboli P, Gomez JA, Czerniak BA.

Hum Pathol. 2010 May;41(5):663-71. doi: 10.1016/j.humpath.2009.10.005. Epub 2009 Dec 11.


Smooth muscle differentiation identifies two classes of poorly differentiated pleomorphic sarcomas with distinct outcome.

Pérot G, Mendiboure J, Brouste V, Velasco V, Terrier P, Bonvalot S, Guillou L, Ranchère-Vince D, Aurias A, Coindre JM, Chibon F.

Mod Pathol. 2014 Jun;27(6):840-50. doi: 10.1038/modpathol.2013.205. Epub 2013 Nov 29.


Expression of smooth muscle markers in so called malignant fibrous histiocytomas.

Hasegawa T, Hasegawa F, Hirose T, Sano T, Matsuno Y.

J Clin Pathol. 2003 Sep;56(9):666-71.


Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.

Fadare O, Renshaw IL, Liang SX.

Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):352-9. doi: 10.1097/PAI.0b013e3182013441.


A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.

Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB.

Mod Pathol. 2009 Dec;22(12):1519-31. doi: 10.1038/modpathol.2009.122. Epub 2009 Sep 4.


Pleomorphic leiomyosarcoma: clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma.

Oda Y, Miyajima K, Kawaguchi K, Tamiya S, Oshiro Y, Hachitanda Y, Oya M, Iwamoto Y, Tsuneyoshi M.

Am J Surg Pathol. 2001 Aug;25(8):1030-8.


Supplemental Content

Support Center